GlassScriptPhysician profile
Paul Reyes
NPI 1689636631
$2,402.72
in general payments reported to CMS, 2019-2025
26 companies · $317 in 2025
The $317 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $702 · 2021: $674 · 2022: $82.76 · 2023: $130 · 2024: $156 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $976.81 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $188.43 | 2021-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $154.93 | 2019-2025 | Gardasil 9, Vaxelis, Rotateq |
| Pfizer INC. | $146.03 | 2019-2025 | |
| Sanofi Pasteur INC. | $101.04 | 2019-2025 | |
| Cranial Technologies, INC | $95.11 | 2019-2025 | Doc Band |
| Corium, LLC | $87.97 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $81.15 | 2019-2022 | |
| Adlon Therapeutics L.P. | $74.93 | 2019-2021 | |
| Genentech USA, INC. | $65.20 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $60.77 | 2025 | Voxzogo 1.2mg |
| Neos Therapeutics, LP | $49.31 | 2019-2022 | |
| Aytu Biopharma, INC. | $45.07 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.53 | 2020-2021 | |
| Phadia US INC. | $34.23 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $24.31 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $23.97 | 2025 | Neffy |
| Abbott Laboratories | $19.67 | 2025 | Id Now Instrument |
| Verrica Pharmaceuticals INC. | $19.09 | 2023 | Ycanth |
| Cipher Pharmaceuticals US LLC | $18.21 | 2025 | Spinosad, Natroba |
| Galderma Laboratories, L.P. | $17.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.60 | 2019 | |
| Glaxosmithkline, LLC. | $15.58 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.53 | 2025 | Zoryve |
| Vertical Pharmaceuticals, LLC | $14.94 | 2025 | Relexxii |
| Tris Pharma INC | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.